← Back to patent-cliff list
LY-4395089
Tier C — Watch / tradeLY-4395089
Eli Lilly and Company
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：Updating
Indications (approved)：Crohn's disease, Ulcerative colitis
Regional status
US
Phase II
2026-05-04
EU
Phase II
2026-05-04
China
Phase II
2026-05-04
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of LY-4395089?
Approved indications include: Crohn's disease, Ulcerative colitis.
When does the LY-4395089 patent expire?
No public expiry year is available for LY-4395089 yet; this page updates once verified.
How do I get a quote for LY-4395089 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-29